NCT01769547View on ClinicalTrials.gov

A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Advanced Malignant Pleural MesotheliomaMPM
Interventions
DRUG

Dovitinib

Treatment continued until Disease Progression, Toxicity, or patient withdrawal.

Trial Locations (5)

T2N 4N2

Tom Baker Cancer Centre, Calgary

P3E 5J1

Northeast Cancer Centre, Health Sciences North, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre, Hamilton

K1H 8L6

Ottawa General Hospital Cancer Centre, Ottawa

M5G 1X6

Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER